Compare Novartis with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs TORRENT PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS TORRENT PHARMA NOVARTIS/
TORRENT PHARMA
 
P/E (TTM) x 1,926.9 36.7 5,249.7% View Chart
P/BV x 25.6 9.3 275.3% View Chart
Dividend Yield % 1.7 0.7 263.5%  

Financials

 NOVARTIS   TORRENT PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-19
TORRENT PHARMA
Mar-19
NOVARTIS/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs9801,964 49.9%   
Low Rs6001,245 48.2%   
Sales per share (Unadj.) Rs198.7453.4 43.8%  
Earnings per share (Unadj.) Rs21.025.8 81.3%  
Cash flow per share (Unadj.) Rs22.362.3 35.7%  
Dividends per share (Unadj.) Rs10.0017.00 58.8%  
Dividend yield (eoy) %1.31.1 119.5%  
Book value per share (Unadj.) Rs307.5279.2 110.1%  
Shares outstanding (eoy) m24.69169.22 14.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.03.5 112.3%   
Avg P/E ratio x37.762.2 60.6%  
P/CF ratio (eoy) x35.525.8 137.8%  
Price / Book Value ratio x2.65.7 44.7%  
Dividend payout %47.765.9 72.3%   
Avg Mkt Cap Rs m19,508271,513 7.2%   
No. of employees `0000.613.6 4.3%   
Total wages/salary Rs m1,17114,038 8.3%   
Avg. sales/employee Rs Th8,445.45,642.6 149.7%   
Avg. wages/employee Rs Th2,015.71,032.4 195.2%   
Avg. net profit/employee Rs Th891.0320.9 277.7%   
INCOME DATA
Net Sales Rs m4,90776,728 6.4%  
Other income Rs m783571 137.2%   
Total revenues Rs m5,68977,299 7.4%   
Gross profit Rs m12319,831 0.6%  
Depreciation Rs m326,177 0.5%   
Interest Rs m165,038 0.3%   
Profit before tax Rs m8589,187 9.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m3401,254 27.1%   
Profit after tax Rs m5184,363 11.9%  
Gross profit margin %2.525.8 9.7%  
Effective tax rate %39.613.6 290.5%   
Net profit margin %10.65.7 185.5%  
BALANCE SHEET DATA
Current assets Rs m8,05550,375 16.0%   
Current liabilities Rs m1,85051,653 3.6%   
Net working cap to sales %126.4-1.7 -7,592.6%  
Current ratio x4.41.0 446.4%  
Inventory Days Days4592 48.9%  
Debtors Days Days3468 49.7%  
Net fixed assets Rs m15083,648 0.2%   
Share capital Rs m123846 14.6%   
"Free" reserves Rs m7,46946,397 16.1%   
Net worth Rs m7,59247,244 16.1%   
Long term debt Rs m039,129 0.0%   
Total assets Rs m9,824141,209 7.0%  
Interest coverage x54.92.8 1,945.8%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x0.50.5 91.9%   
Return on assets %5.46.7 81.6%  
Return on equity %6.89.2 73.8%  
Return on capital %11.512.3 93.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5822,103 0.3%   
Fx outflow Rs m1,3265,522 24.0%   
Net fx Rs m-1,26916,581 -7.7%   
CASH FLOW
From Operations Rs m-1,94317,981 -10.8%  
From Investments Rs m2,742-2,413 -113.7%  
From Financial Activity Rs m-298-13,145 2.3%  
Net Cashflow Rs m5012,380 21.1%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 7.0 28.5%  
FIIs % 1.6 12.6 12.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 8.8 244.3%  
Shareholders   41,647 26,511 157.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  STRIDES PHARMA SCIENCE  FDC  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 883 Points Today(Closing)

Indian share markets nosedived and registered sharp losses in today's volatile session following a strong second wave of Covid-19 in the country.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Apr 19, 2021 03:36 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - FDC COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS